VIET NAM MEDICINAL MATERIALS JOINT STOCK COMPANY

VIET NAM MEDICINAL MATERIALS JOINT STOCK COMPANY (Vietnamese name: CÔNG TY CỔ PHẦN DƯỢC LIỆU VIỆT NAM, abbreviation VIETMEC; JSC) is a Vietnamese pharmaceutical and medicinal materials enterprise operating in the production and distribution of herbal medicines and health supplements. The company is registered under Business ID 0105196582 and was established on 16 March 2011.

The company’s head office is located at Area 8, Phu Ninh Commune, Phu Tho Province, Vietnam. From this base, the company has expanded its commercial presence through branches in major cities such as Hanoi, Hai Phong, and Ho Chi Minh City, allowing it to distribute medicinal products across Vietnam.

VIET NAM MEDICINAL MATERIALS JOINT STOCK COMPANY focuses on producing traditional medicines, herbal supplements, and medicinal materials while also trading pharmaceutical products and medical equipment. The company also participates in research activities related to medicinal plants, natural sciences, and agricultural cultivation of herbal raw materials.

Nguyen V. C. chairs the company, while Vu T. T. serves as General Director. With approximately 230 employees, the enterprise operates on a moderate scale within Vietnam’s herbal medicine and pharmaceutical supply chain.

Financially, the company maintains a relatively stable balance sheet. Total assets are estimated at around USD 67 million, supported by equity of roughly USD 30 million. Revenue has grown steadily to nearly USD 65 million, while profit remains close to USD 2 million. Although the company continues to expand its revenue base, profitability remains relatively modest compared with total sales.

From a risk management perspective, the herbal pharmaceutical sector presents several structural challenges. Companies operating in this industry must comply with increasingly strict regulatory requirements related to pharmaceutical quality, safety standards, and traceability of medicinal materials. Failure to meet these requirements could affect product approvals and market access.

Another key risk concerns the supply chain's dependence on medicinal plant cultivation. Variations in agricultural yields, environmental conditions, and quality control of herbal inputs may affect production stability. Additionally, companies involved in herbal medicine production face strong competition from both domestic pharmaceutical firms and imported healthcare products.